https://www.selleckchem.com/pr....oducts/Mycophenolic-
s demonstrated poor patency rates, higher primary patency is noted for stenting in the first two years. Coupled with low complication rates, this highlights a potential benefit of stenting as first line treatment for CVO. Allowing for overall poor quality of current studies, even this short-term improvement in primary patency may benefit haemodialysis patients. Further research with randomised control trials as well as assessment of adjuvant techniques such as drug coated stents/balloons, anticoagulant therapy a
Like
Comment
Share
